EB

Enigma Biomedical - USA Announces Appointment of Hartmuth Kolb, PhD as Chief Scientific Officer

Retrieved on: 
Tuesday, February 13, 2024

Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).

Key Points: 
  • Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).
  • Dr. Kolb’s passion for innovation and scientific rigor has driven his extensive career and broad recognition.
  • He will join Enigma at the beginning of March, 2024.
  • In his 10 year tenure at Johnson & Johnson Innovative Medicine, he served as the Vice President, Neuroscience Biomarkers and Global Head of Imaging.

LIFT Intersects 11 m at 1.52% Li₂O at its Nite pegmatite, Yellowknife Lithium Project, NWT

Retrieved on: 
Tuesday, February 13, 2024

YLP-0174 explored the Nite pegmatite approximately 100 m from its northern end and 50 m beneath the surface.

Key Points: 
  • YLP-0174 explored the Nite pegmatite approximately 100 m from its northern end and 50 m beneath the surface.
  • Drilling intersected three pegmatite dykes ranging from 2-5 m wide for cumulative pegmatite of 9 m over 27 m of core.
  • New drilling intersected a 16 m dyke preceded by four 1-7 m dykes for cumulative pegmatite of 31 m over 72 m of drill core.
  • Figure 3 – Cross-section illustrating YLP-0177 with results as shown in the Nite pegmatite dyke with a 11 m interval of 1.52% Li2O.

Eventbrite Announces Date of Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Tuesday, February 6, 2024

Eventbrite, Inc. (NYSE: EB), a global events marketplace, announced that it will release its financial results for the fourth quarter ended December 31, 2023, after the market closes on Tuesday, February 27, 2024.

Key Points: 
  • Eventbrite, Inc. (NYSE: EB), a global events marketplace, announced that it will release its financial results for the fourth quarter ended December 31, 2023, after the market closes on Tuesday, February 27, 2024.
  • An archived webcast of the conference call will be accessible on Eventbrite’s Investor Relations page, https://investor.eventbrite.com .

LIFT Intersects 23 m at 1.25% Li₂O at its Ki pegmatite, Yellowknife Lithium Project, NWT

Retrieved on: 
Tuesday, January 30, 2024

YLP-0165 tested the Ki pegmatite approximately 200 m from its southern mapped extent and 50 m vertically beneath the surface, as well as 50 m down-dip of YLP-0118 (0.96% Li2O over 1 m).

Key Points: 
  • YLP-0165 tested the Ki pegmatite approximately 200 m from its southern mapped extent and 50 m vertically beneath the surface, as well as 50 m down-dip of YLP-0118 (0.96% Li2O over 1 m).
  • Drilling intersected a 23 m wide pegmatite dyke that returned 1.25% Li2O over 23 m (Table 1 & 2, Figures 2 & 3).
  • Figure 3 – Cross-section illustrating YLP-0165 with results as shown in the Ki pegmatite dyke with a 23 m interval of 1.25% Li2O.
  • Drilling intersected three dykes over a 35 m interval of core, with dykes ranging from 4-9 m in width and summing to 17 m of pegmatite.

BPGbio Appoints Ritesh Srivastava as General Counsel

Retrieved on: 
Monday, January 22, 2024

BPGbio, Inc ., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the appointment of Ritesh Srivastava as General Counsel.

Key Points: 
  • BPGbio, Inc ., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the appointment of Ritesh Srivastava as General Counsel.
  • Mr. Srivastava joins BPGbio from Spectrum Pharmaceuticals, a publicly traded biopharmaceutical company, where he held several leadership roles for over five years, including most recently as Global Compliance Officer.
  • At Spectrum, Mr. Srivastava provided leadership and counsel in all legal and compliance matters in acquiring, developing, and commercializing novel and targeted drug products in hematology and oncology.
  • “Ritesh Srivastava is a proven leader in the biopharma industry and a skilled corporate counsel,” said Niven R. Narain , Ph.D., CEO and President of BPGbio.

LIFT Intersects 27 m at 1.26% Li2O and 22 m at 1.53% Li2O at its Fi Main pegmatite, Yellowknife Lithium Project, NWT

Retrieved on: 
Tuesday, January 16, 2024

The Fi Main pegmatite comprises a 10-100 m wide corridor of 1-5 dykes that dip between 70°-85° to the west-northwest and extends for at least 1,500 m on surface.

Key Points: 
  • The Fi Main pegmatite comprises a 10-100 m wide corridor of 1-5 dykes that dip between 70°-85° to the west-northwest and extends for at least 1,500 m on surface.
  • YLP-0141 tested the Fi Main pegmatite approximately 400 m from its northern mapped extent and 50 m vertically beneath the surface.
  • Figure 3 – Cross-section illustrating YLP-0141 with results as shown in the Fi Main pegmatite dyke with a 27 m interval of 1.26% Li2O.
  • Figure 4 – Cross-section illustrating YLP-0147 with results as shown in the Fi Main pegmatite dyke with a 22 m interval of 1.53% Li2O.

Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa

Retrieved on: 
Tuesday, December 19, 2023

BOSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced today that the U.S. Food and Drug Administration (FDA) approved FILSUVEZ® (birch triterpenes) topical gel for the treatment of partial thickness wounds in patients 6 months and older with Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB). FILSUVEZ is the first approved treatment for wounds associated with JEB, a rare, moderate-to-severe form of EB with blisters beginning in infancy. FILSUVEZ joined the Chiesi portfolio as part of the agreement reached during the acquisition of Amryt Pharma in January of this year.

Key Points: 
  • FILSUVEZ is the first approved treatment for wounds associated with JEB, a rare, moderate-to-severe form of EB with blisters beginning in infancy.
  • FILSUVEZ joined the Chiesi portfolio as part of the agreement reached during the acquisition of Amryt Pharma in January of this year.
  • "At Chiesi Global Rare Diseases we are driven by a need to alleviate the burdens faced in the rare disease community by providing innovative therapies and solutions that address debilitating unmet needs.” Giacomo Chiesi, Head of Chiesi Global Rare Diseases, said.
  • FILSUVEZ topical gel is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older.

Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments

Retrieved on: 
Monday, November 13, 2023

CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the third quarter of 2023 and provided corporate updates.

Key Points: 
  • The FDA also agreed that retroviral vector manufactured at Abeona and Indiana University appear comparable based on the data that Abeona provided in its briefing book.
  • If accepted with Priority Review, Abeona expects potential BLA approval in the second quarter of 2024.
  • Abeona estimates that its cash and cash equivalents, restricted cash and short-term investments as of September 30, 2023 are sufficient resources to fund operations into the fourth quarter of 2024.
  • Abeona Therapeutics will host a conference call and webcast today, November 13, 2023, at 8:30 a.m.

Patra Accelerates International Expansion Into Canada

Retrieved on: 
Wednesday, November 29, 2023

Patra, a leading provider of technology-enabled insurance outsourcing services, is delighted to announce its expansion into the Canadian market.

Key Points: 
  • Patra, a leading provider of technology-enabled insurance outsourcing services, is delighted to announce its expansion into the Canadian market.
  • The expansion into Canada marks a significant step in Patra’s global expansion plans to offer comprehensive and unique insurance service offerings to the Canadian market.
  • “Canada is a natural market expansion for Patra with an initial set of customers already established.
  • Sharon brings decades of Canadian insurance experience to market, most recently with Trufla Technology, Apollo Insurance, and First Insurance Funding of Canada.

Leading AI-Powered Biopharma BPGbio Appoints Kenin Spivak to Board of Directors

Retrieved on: 
Monday, November 13, 2023

BPGbio, Inc ., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak , a highly regarded executive, entrepreneur, financier, author, and attorney to its Board of Directors , as an independent director.

Key Points: 
  • BPGbio, Inc ., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak , a highly regarded executive, entrepreneur, financier, author, and attorney to its Board of Directors , as an independent director.
  • “We are thrilled to welcome Kenin Spivak to the BPGbio Board,” said Daniel Elliott , Executive Chairman of BPGbio.
  • He has served as a director of, and advisor to, several healthcare and technology companies.
  • He is admitted to practice law in California and New York, and holds numerous securities licenses, including Series 24 (general securities principal).